3 Oversold Stocks Down More than 40% This Year

Tuesday, May 11, 2021 | MarketBeat Staff
3 Oversold Stocks Down More than 40% This Year

Like any year in the stock market, 2021 has had its share of big winners and big losers. Sometimes the losers of today can turn into the winners of tomorrow and vice versa.

Although a stock could be down big for good reason and even have more downside, at a certain point some selloffs become emotionally driven. This can create a disconnect between the fundamentals of a company and the price at which its stock is trading.

Here we look at three stocks that are down at least 40% this year and have entered oversold territory. All participate in long-term growth markets and at current levels offer investors a bargain entry point.

Is the Peloton Interactive Stock Selloff a Buy Opportunity?

Few stocks performed as well as Peloton Interactive (NASDAQ:PTON) did last year. Few have performed as poorly in 2021. After soaring more than 400% in 2020, the maker of technology-based exercise equipment is down 45% year-to-date. But while the company has hit a rough patch, it has the endurance to keep moving higher over the long haul.

Part of the decline relates to Peloton's association with the stay-at-home economy. The near-term boost of COVID demand is fading as anticipated, but that doesn't mean the company can't build upon its leadership position in the interactive home exercise space. Another factor has been the attack on high P/E stocks as investors rotate into low multiple, cyclical names. It also hasn't helped matters that Peloton announced a voluntary recall on its Tread+ treadmills—and soon after refuting the Consumer Product Safety Commission's concerns stemming from a tragic death of a child and dozens of other non-fatal incidents.

While these matters are not to be taken lightly, in the long run, they will likely amount to a temporary bout of reputational damage for Peloton. Its expanding lineup of fitness equipment and subscription-based services should continue to be an effective business model in a world that is now hyper-focused on health and wellness. Peloton has planted strong roots as an alternative or complement to gym memberships and will have ample opportunity to leverage its platform in the post-pandemic economy.

Is JFrog Stock Oversold?

After the usual IPO euphoria faded after a few weeks, JFrog (NASDAQ:FROG) shares have plummeted. The self-proclaimed "liquid software" company has seen its share price cut in half compared to its September 2020 debut amid a weakening investor appetite for high priced, unprofitable tech stocks.

JFrog's comprehensive platform for software developers certainly has potential to deliver growth. It has already gathered over 6,000 customers and millions of users that find value in its continuous software release solutions. This has coincided with 40% revenue growth over the last 12 months and a strong 130% net dollar retention rate, a common measure of customer 'stickiness'.

Last week JFrog reported a strong start to fiscal 2021 reporting a much narrower net loss than the Street expected. This went largely unnoticed as inflation worries caused the market to selloff anything with a high valuation.

Eventually the market will recognize it has unjustly pummeled a company with a leading position in a growing $22 billion market. It should also gain an appreciation for JFrog's robust annual recurring revenue (ARR) numbers that represent a steady stream of visible income.

At some point in the near future investors will find high growth tech names attractive again. With JFrog trading outside its lower Bollinger band and having good sell-side backing, it is likely to take one of the biggest leaps forward. Even the most bearish price target on the Street, $44, is $10 above where JFrog is currently priced.

From Where will Haemonetics Derive Growth?

Healthcare stock Haemonetics (NYSE:HAE) has plunged 50% this year. The main dagger was the company's announcement that key customer CSL Plasma would not be renewing its contract with Haemonetics in June 2022. This is undoubtedly a devastating blow given the volume of Plasma Collection System (PCS) devices and disposable kits that CSL is receiving.

In response, Haemonetics dropped 36% on April 19th and investors has since wanted nothing to do with it. But sometimes when a stock is woefully out of favor, it is a good time to scoop up some cheap shares.

That seems to be the case with Haemonetics. The provider of blood management solutions for hospitals and plasma collection centers not only has more than a year to make up for the lost CSL revenue but opportunities to derive growth from other areas.

Haemonetics is trading well below its historical P/E averages and patient investors have an opportunity to get an established player in a steadily growing part of the healthcare sector. The company holds the top position in both the plasma collection equipment and software markets and has few competitors.

Plasma-based therapeutics are increasingly being developed to treat a range of medical diseases and conditions with hundreds of clinical trials underway. As this space continues to grow, Haemonetics will grow along with it as a supplier plasma collection technology and disposables.

With Haemonetics scheduled to report quarterly results on May 13th, investors may want to wait to hear what management has to say in case the market overreacts yet again. This could create an even cheaper entry point.

Featured Article: What member countries make up the G-20?


7 Precious Metals Stocks That Will Keep Your Portfolio On Trend

The growing acceptance of cryptocurrency is beginning to make mainstream investors rethink their idea of “store of value.” The trendy possibilities of Bitcoin, Ethereum, and any of the dozens of altcoins that exist on the blockchain are trending like the latest fashion.

However, the thing about fashion is that the more things change the more things stay the same. Just like the simple black dress that won’t go out of fashion, the same can be said for precious metals stocks. One way to think about it would be to say that the existence of a growing cryptocurrency market doesn’t change the value of precious metals.

Precious metals have long been known to be a safe-haven asset in times of market volatility and economic crisis. In fact, during the Covid-19 pandemic, gold prices surged about 30% breaking the $2,000 mark for the first time in its history. This was at a time when the prices of many cryptocurrencies were falling.

And precious metals have also been seen as a hedge against inflation, which seems like more of a certainty with the Federal Reserve’s pledge to keep interest rates at historically low rates into 2023.

Whether you’re looking to take your first steps at crafting a precious metals portfolio or if you want to fine-tune the one you have, we believe this special presentation is a good place to start your research. We’ve identified seven precious metals stocks that look to retain their allure in 2021.

View the "7 Precious Metals Stocks That Will Keep Your Portfolio On Trend".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
JFrog (FROG)1.9$45.63-3.4%N/A-304.20Hold$69.30
Peloton Interactive (PTON)2.1$112.09-0.9%N/A180.79Buy$140.39
Haemonetics (HAE)2.2$59.84-0.4%N/A38.61Buy$97.33
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.